Study details
Enrolling now
Safety and Tolerability Trial of Lumateperone in Pediatric Patients
Intra-Cellular Therapies, Inc.
NCT IDNCT06229210ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
500
Study length
about 3.9 years
Ages
5–17
Locations
47 sites in AR, AZ, CA +14
About this study
Researchers are testing the safety and tolerability of a medication called lumateperone in children with schizophrenia, bipolar disorder, or autism spectrum disorder. The trial will last for 26 weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lumateperone
PhasePhase 3
DrugLumateperone
Routeoral
Primary goalIncidence of Common Adverse Events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low4%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
lumateperone
Drug routes
oral (Oral Capsule)
Endpoints
Primary: Incidence of Common Adverse Events
Body systems
Psychiatry / Mental Health